Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects

NCT00841763 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00841763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00841763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2008
Completion date
November 30, 2009
Enrollment
3,647 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pandemic influenza disease